Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.

Vitelli A, Quirion MR, Lo CY, Misplon JA, Grabowska AK, Pierantoni A, Ammendola V, Price GE, Soboleski MR, Cortese R, Colloca S, Nicosia A, Epstein SL.

PLoS One. 2013;8(3):e55435. doi: 10.1371/journal.pone.0055435. Epub 2013 Mar 11.

2.

SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors.

Piccolo P, Vetrini F, Mithbaokar P, Grove NC, Bertin T, Palmer D, Ng P, Brunetti-Pierri N.

Mol Ther. 2013 Apr;21(4):767-74. doi: 10.1038/mt.2012.287. Epub 2013 Jan 29.

3.

Reduction of ethanol consumption in alcohol-preferring rats by dual expression gene transfer.

Rivera-Meza M, Quintanilla ME, Tampier L.

Alcohol Alcohol. 2012 Mar-Apr;47(2):102-8. doi: 10.1093/alcalc/agr161. Epub 2012 Jan 2.

4.

The role of endosomal escape and mitogen-activated protein kinases in adenoviral activation of the innate immune response.

Smith JS, Xu Z, Tian J, Palmer DJ, Ng P, Byrnes AP.

PLoS One. 2011;6(10):e26755. doi: 10.1371/journal.pone.0026755. Epub 2011 Oct 27.

5.

Helper-dependent adenoviral vectors for liver-directed gene therapy.

Brunetti-Pierri N, Ng P.

Hum Mol Genet. 2011 Apr 15;20(R1):R7-13. doi: 10.1093/hmg/ddr143. Epub 2011 Apr 5. Review.

6.

Adenoviral vector immunity: its implications and circumvention strategies.

Ahi YS, Bangari DS, Mittal SK.

Curr Gene Ther. 2011 Aug;11(4):307-20. Review.

7.

Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins.

O'Neill AM, Smith AN, Spangler EA, Whitley EM, Schleis SE, Bird RC, Curiel DT, Thacker EE, Smith BF.

Cancer Biol Ther. 2011 Apr 1;11(7):651-8. Epub 2011 Apr 1.

8.

Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Xu Z, Smith JS, Tian J, Byrnes AP.

Mol Ther. 2010 Mar;18(3):609-16. doi: 10.1038/mt.2009.279. Epub 2009 Dec 1.

9.

Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Tian J, Xu Z, Smith JS, Hofherr SE, Barry MA, Byrnes AP.

J Virol. 2009 Jun;83(11):5648-58. doi: 10.1128/JVI.00082-09. Epub 2009 Mar 25.

10.

Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy.

Hofherr SE, Senac JS, Chen CY, Palmer DJ, Ng P, Barry MA.

Hum Gene Ther. 2009 Feb;20(2):169-80. doi: 10.1089/hum.2008.158.

11.

Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.

Boquet MP, Wonganan P, Dekker JD, Croyle MA.

J Pharmacol Toxicol Methods. 2008 Nov-Dec;58(3):222-32. doi: 10.1016/j.vascn.2008.07.003. Epub 2008 Aug 3.

12.

The effect of surface demineralization of cortical bone allograft on the properties of recombinant adeno-associated virus coatings.

Yazici C, Yanoso L, Xie C, Reynolds DG, Samulski RJ, Samulski J, Yannariello-Brown J, Gertzman AA, Zhang X, Awad HA, Schwarz EM.

Biomaterials. 2008 Oct;29(28):3882-7. doi: 10.1016/j.biomaterials.2008.06.007. Epub 2008 Jun 30.

13.

Current strategies and future directions for eluding adenoviral vector immunity.

Bangari DS, Mittal SK.

Curr Gene Ther. 2006 Apr;6(2):215-26. Review.

Items per page

Supplemental Content

Write to the Help Desk